Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

2.

Passivation of Plasmonic Colors on Bulk Silver by Atomic Layer Deposition of Aluminum Oxide.

Guay JM, Killaire G, Gordon PG, Barry ST, Berini P, Weck A.

Langmuir. 2018 May 1;34(17):4998-5010. doi: 10.1021/acs.langmuir.8b00210. Epub 2018 Apr 16.

PMID:
29570308
3.

The Chemistry of Inorganic Precursors during the Chemical Deposition of Films on Solid Surfaces.

Barry ST, Teplyakov AV, Zaera F.

Acc Chem Res. 2018 Mar 20;51(3):800-809. doi: 10.1021/acs.accounts.8b00012. Epub 2018 Feb 28.

PMID:
29489341
4.

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Little RA, Barjat H, Hare JI, Jenner M, Watson Y, Cheung S, Holliday K, Zhang W, O'Connor JPB, Barry ST, Puri S, Parker GJM, Waterton JC.

Magn Reson Imaging. 2018 Feb;46:98-105. doi: 10.1016/j.mri.2017.11.008. Epub 2017 Nov 14.

5.

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.

Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling J, Staniszewska A, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST.

Clin Cancer Res. 2017 Dec 15;23(24):7584-7595. doi: 10.1158/1078-0432.CCR-17-0676. Epub 2017 Oct 2.

PMID:
28972046
6.

Developing PreDICT - a fully integrated data platform for preclinical in vivo data: learning from experience.

Jones RDO, Cooke M, Hinchliffe J, Morley J, Barry ST.

Drug Discov Today. 2017 Oct;22(10):1539-1546. doi: 10.1016/j.drudis.2017.07.014. Epub 2017 Aug 9. Review.

PMID:
28800878
7.

TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis.

Cammareri P, Vincent DF, Hodder MC, Ridgway RA, Murgia C, Nobis M, Campbell AD, Varga J, Huels DJ, Subramani C, Prescott KLH, Nixon C, Hedley A, Barry ST, Greten FR, Inman GJ, Sansom OJ.

Cell Death Differ. 2017 Oct;24(10):1681-1693. doi: 10.1038/cdd.2017.92. Epub 2017 Jun 16.

8.

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.

Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN, Hattersley M, Wen S, Curtis NJ, Pilling JE, Pease EJ, Barry ST.

Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14.

9.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

PMID:
28202458
10.

Automated image analysis of intra-tumoral and peripheral endocrine organ vascular bed regression using 'Fibrelength' as a novel structural biomarker.

Hargreaves A, Bigley A, Price S, Kendrew J, Barry ST.

J Appl Toxicol. 2017 Aug;37(8):902-912. doi: 10.1002/jat.3438. Epub 2017 Feb 10.

PMID:
28186326
11.

Surface chemistry of group 11 atomic layer deposition precursors on silica using solid-state nuclear magnetic resonance spectroscopy.

Pallister PJ, Barry ST.

J Chem Phys. 2017 Feb 7;146(5):052812. doi: 10.1063/1.4968021.

PMID:
28178840
12.

Effect of the nature of the substrate on the surface chemistry of atomic layer deposition precursors.

Yao Y, Coyle JP, Barry ST, Zaera F.

J Chem Phys. 2017 Feb 7;146(5):052806. doi: 10.1063/1.4966201.

PMID:
28178813
13.

Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.

England RM, Hare JI, Barnes J, Wilson J, Smith A, Strittmatter N, Kemmitt PD, Waring MJ, Barry ST, Alexander C, Ashford MB.

J Control Release. 2017 Feb 10;247:73-85. doi: 10.1016/j.jconrel.2016.12.034. Epub 2016 Dec 30.

PMID:
28043863
14.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP.

Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6.

15.

The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.

Maynard J, Emmas SA, Blé FX, Barjat H, Lawrie E, Hancox U, Oakes D, Polanska UM, Barry ST.

EJNMMI Res. 2016 Dec;6(1):62. doi: 10.1186/s13550-016-0220-9. Epub 2016 Aug 11.

16.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP.

Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2.

17.

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST.

Adv Drug Deliv Rev. 2017 Jan 1;108:25-38. doi: 10.1016/j.addr.2016.04.025. Epub 2016 Apr 29. Review.

18.

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, Davies BR.

Oncotarget. 2016 Apr 19;7(16):22128-39. doi: 10.18632/oncotarget.8031.

19.

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.

Bradford JR, Wappett M, Beran G, Logie A, Delpuech O, Brown H, Boros J, Camp NJ, McEwen R, Mazzola AM, D'Cruz C, Barry ST.

Oncotarget. 2016 Apr 12;7(15):20773-87. doi: 10.18632/oncotarget.8014.

20.

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.

Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST.

Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355.

21.

Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition.

Horton ER, Humphries JD, Stutchbury B, Jacquemet G, Ballestrem C, Barry ST, Humphries MJ.

J Cell Biol. 2016 Feb 1;212(3):349-64. doi: 10.1083/jcb.201508080.

22.

Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression.

Estrada MF, Rebelo SP, Davies EJ, Pinto MT, Pereira H, Santo VE, Smalley MJ, Barry ST, Gualda EJ, Alves PM, Anderson E, Brito C.

Biomaterials. 2016 Feb;78:50-61. doi: 10.1016/j.biomaterials.2015.11.030. Epub 2015 Nov 19.

23.

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices.

Davies EJ, Dong M, Gutekunst M, Närhi K, van Zoggel HJ, Blom S, Nagaraj A, Metsalu T, Oswald E, Erkens-Schulze S, Delgado San Martin JA, Turkki R, Wedge SR, af Hällström TM, Schueler J, van Weerden WM, Verschuren EW, Barry ST, van der Kuip H, Hickman JA.

Sci Rep. 2015 Dec 9;5:17187. doi: 10.1038/srep17187.

24.

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

Pommier AJ, Farren M, Patel B, Wappett M, Michopoulos F, Smith NR, Kendrew J, Frith J, Huby R, Eberlein C, Campbell H, Womack C, Smith PD, Robertson J, Morgan S, Critchlow SE, Barry ST.

Cell Metab. 2016 Jan 12;23(1):77-93. doi: 10.1016/j.cmet.2015.10.015. Epub 2015 Nov 25.

25.

PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.

Hall AP, Ashton S, Horner J, Wilson Z, Reens J, Richmond GH, Barry ST, Wedge SR.

Toxicol Pathol. 2016 Jan;44(1):98-111. doi: 10.1177/0192623315613452. Epub 2015 Nov 3.

PMID:
26534939
26.

The effect of ALD-grown Al₂O₃ on the refractive index sensitivity of CVD gold-coated optical fiber sensors.

Mandia DJ, Zhou W, Ward MJ, Joress H, Sims JJ, Giorgi JB, Albert J, Barry ST.

Nanotechnology. 2015 Oct 30;26(43):434002. doi: 10.1088/0957-4484/26/43/434002. Epub 2015 Oct 5.

PMID:
26437035
27.

Absolute near-infrared refractometry with a calibrated tilted fiber Bragg grating.

Zhou W, Mandia DJ, Barry ST, Albert J.

Opt Lett. 2015 Apr 15;40(8):1713-6. doi: 10.1364/OL.40.001713.

PMID:
25872055
28.

Tumour stromal morphology impacts nanomedicine cytotoxicity in patient-derived xenografts.

Delgado San Martin JA, Hare JI, Yates JW, Barry ST.

Nanomedicine. 2015 Jul;11(5):1247-52. doi: 10.1016/j.nano.2015.02.007. Epub 2015 Mar 6.

PMID:
25752857
29.

WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.

Boulter L, Guest RV, Kendall TJ, Wilson DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N, Barry ST, Wigmore SJ, Sansom OJ, Forbes SJ.

J Clin Invest. 2015 Mar 2;125(3):1269-85. doi: 10.1172/JCI76452. Epub 2015 Feb 17.

30.

Anisotropic effective permittivity of an ultrathin gold coating on optical fiber in air, water and saline solutions.

Zhou W, Mandia DJ, Barry ST, Albert J.

Opt Express. 2014 Dec 29;22(26):31665-76. doi: 10.1364/OE.22.031665.

PMID:
25607137
31.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.

Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

32.

Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Rossant CJ, Carroll D, Huang L, Elvin J, Neal F, Walker E, Benschop JJ, Kim EE, Barry ST, Vaughan TJ.

MAbs. 2014;6(6):1425-38. doi: 10.4161/mabs.34376.

33.

Mechanisms that influence tumour response to VEGF-pathway inhibitors.

Smith NR, Wedge SR, Pommier A, Barry ST.

Biochem Soc Trans. 2014 Dec;42(6):1601-7. doi: 10.1042/BST20140261. Review.

PMID:
25399577
34.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

35.

Tumor stromal phenotypes define VEGF sensitivity--response.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2014 Oct 1;20(19):5141. doi: 10.1158/1078-0432.CCR-14-0681. No abstract available.

36.

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.

Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.

PMID:
25220373
37.

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.

Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jürgensmeier JM.

Br J Cancer. 2014 Oct 14;111(8):1590-604. doi: 10.1038/bjc.2014.436. Epub 2014 Aug 14.

38.

Therapeutic targeting of integrin αvβ6 in breast cancer.

Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF.

J Natl Cancer Inst. 2014 Jun 28;106(8). pii: dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug.

39.

E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling.

Eberlein C, Rooney C, Ross SJ, Farren M, Weir HM, Barry ST.

Oncogene. 2015 Feb 5;34(6):704-16. doi: 10.1038/onc.2013.600. Epub 2014 Feb 3.

PMID:
24488011
40.

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.

Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM.

Br J Cancer. 2013 Nov 26;109(11):2765-73. doi: 10.1038/bjc.2013.649. Epub 2013 Oct 22.

41.

High-content analysis to leverage a robust phenotypic profiling approach to vascular modulation.

Isherwood BJ, Walls RE, Roberts ME, Houslay TM, Brave SR, Barry ST, Carragher NO.

J Biomol Screen. 2013 Dec;18(10):1246-59. doi: 10.1177/1087057113499775. Epub 2013 Oct 9.

PMID:
24108119
42.

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2013 Dec 15;19(24):6943-56. doi: 10.1158/1078-0432.CCR-13-1637. Epub 2013 Sep 12.

43.

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.

44.

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib.

Bradford JR, Farren M, Powell SJ, Runswick S, Weston SL, Brown H, Delpuech O, Wappett M, Smith NR, Carr TH, Dry JR, Gibson NJ, Barry ST.

PLoS One. 2013 Jun 19;8(6):e66003. doi: 10.1371/journal.pone.0066003. Print 2013.

45.

Model-based drug discovery: implementation and impact.

Visser SA, Aurell M, Jones RD, Schuck VJ, Egnell AC, Peters SA, Brynne L, Yates JW, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U.

Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012. Epub 2013 May 29. Review.

PMID:
23726890
46.

Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC.

Cancer Res. 2013 Apr 15;73(8):2412-7. doi: 10.1158/0008-5472.CAN-12-4561. Epub 2013 Feb 19.

47.

Polarization-dependent properties of the cladding modes of a single mode fiber covered with gold nanoparticles.

Zhou W, Mandia DJ, Griffiths MB, Bialiayeu A, Zhang Y, Gordon PG, Barry ST, Albert J.

Opt Express. 2013 Jan 14;21(1):245-55. doi: 10.1364/OE.21.000245.

PMID:
23388917
48.

Copper iminopyrrolidinates: a study of thermal and surface chemistry.

Coyle JP, Pallister PJ, Kurek A, Sirianni ER, Yap GP, Barry ST.

Inorg Chem. 2013 Jan 18;52(2):910-7. doi: 10.1021/ic3021035. Epub 2013 Jan 3.

PMID:
23286363
49.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST.

Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29.

PMID:
23108397
50.

Preventing thermolysis: precursor design for volatile copper compounds.

Coyle JP, Kurek A, Pallister PJ, Sirianni ER, Yap GP, Barry ST.

Chem Commun (Camb). 2012 Oct 28;48(84):10440-2. Epub 2012 Sep 19.

PMID:
22990169

Supplemental Content

Loading ...
Support Center